Solutions
Antisense Oligonucleotides (ASO) for Rare Disease Programs
Jump To:
Overview
Built for programs where continuity, speed & rigor matter
Rare disease antisense oligonucleotide (ASO) programs operate under constraints that standard development models don’t accommodate: small batches, compressed timelines, and no tolerance for downstream rework.
Success depends on partners who understand not just how to synthesize oligonucleotides — but how early developmental decisions affect CMC strategy, toxicology studies, and clinical readiness later.
Oligo Factory is a specialized oligonucleotide CDMO providing ASO manufacturing and development support for rare disease therapeutic programs.
BENEFITS & Support
Designed for the Way Rare Disease Antisense Oligonucleotide (ASO) Programs Actually Progress
- Preserve continuity across development stages
From early research material through toxicology studies and first GMP ASO manufacturing, without forcing resets or comparability exercises. - Move quickly without creating downstream CMC risk
Fast turnaround that remains aligned with rising regulatory expectations for ASO development and manufacturing. - Execute small-batch manufacturing with rigor and reproducibility
Processes, analytics, and controls appropriate for very small quantity ASO material - Operate confidently in atypical, highly constrained development paths
Including ultra-rare and n-of-1 ASO programs where timelines, materials, and decision are uniquely constrained
How Oligo Factory Supports Rare Disease Antisense Oligonucleotide (ASO) Programs
As a focused oligonucleotide CDMO, Oligo Factory combines speed with discipline – by design – to support rare disease ASO development and manufacturing.
- Platform continuity from RUO through GMP: Sequences, chemistries, processes, and analytics are developed with GMP ASO manufacturing expectations in mind, helping rare disease programs maintain continuity across development stages.
- Purpose-built small-batch synthesis aligned to toxicology and early clinical needs: Our antisense oligonucleotide synthesis and manufacturing workflows are optimized for turnaround time and reproducibility at the scales rare disease programs actually require.
- Deep ASO chemistry and impurity-control expertise: Extensive experience managing ASO impurity profiles, oligonucleotide impurity control, and comparability challenges before they become limiting to development.
- Experience executing ultra-rare and n-of-1 ASO programs: Including highly constrained and timeline-driven development paths for ultra-rare disease and patient-specific antisense oligonucleotide programs.
- High-touch technical engagement: Dedicated project management with direct access to scientific teams — ensuring programs receive the technical attention required for successful ASO development and manufacturing.
Ideally Suited for…
- Rare disease biotech and therapeutic teams
- CMC leaders responsible for minimizing downstream risk
- Academic translational groups advancing ASOs toward clinical readiness
- Foundations supporting patient-driven and ultra-rare initiatives
If your program depends on small-batch antisense oligonucleotide manufacturing, fast turnaround time, and confidence that today’s work will support tomorrow’s clinical development, Oligo Factory is built to support you.
Partnership in rare disease
A Trusted Partner in Ultra-Rare ASO Development
Oligo Factory is a proud manufacturing partner to n-Lorem Foundation, supporting patient-driven, n-of-1 antisense oligonucleotide (ASO) programs where execution, quality, and turnaround time are critical.
This work reflects the same principles applied across all rare disease ASO manufacturing programs we support: fit-for-purpose rigor, disciplined flexibility, and continuity across stages.
